{"a":[{"_":"Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients","$":{"href":"/pharma/lilly-scores-fda-expansion-mounjaro-reduce-risk-heart-attack-stroke","hreflang":"en"}}]}
RegulatoryapprovedMounjaroPositive
AI Analysis
Summary
Eli Lilly secured FDA approval for Mounjaro to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes, representing a label expansion in its competition with Novo Nordisk in the diabetes market.
Outcome Details
FDA approval for Mounjaro to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes
Importance:8/10
Sentiment:
0.75
FDA approvallabel expansiontype 2 diabetescardiovascular indicationcompetitive landscape
Related Companies
Read the original article
Published by FiercePharma on August 28, 2026 10:19 AM